CHFS - CHF Solutions, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4800
-0.3300 (-40.74%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.8100
Open0.6800
Bid0.4800 x 800
Ask0.4979 x 1000
Day's Range0.4580 - 0.8400
52 Week Range0.4580 - 13.5000
Volume15,542,702
Avg. Volume1,156,788
Market Cap2.244M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 04, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
  • GlobeNewswire

    CHF Solutions, Inc. Announces Pricing of $8.4 Million Underwritten Public Offering

    CHF Solutions, Inc. (CHFS) today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $8.4 million prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The offering is comprised of (1) 3,755,458 Class A Units, priced at a public offering price of $0.55 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $0.55 per share that expires on the fifth anniversary of the date of issuance, and (2) 11,517,269 Class B Units, priced at a public offering price of $0.55 per unit, with each unit consisting of one share of Series H convertible preferred stock, convertible into one share of common stock, and a warrant to purchase one share of common stock with an exercise price of $0.55 per share.

  • GlobeNewswire

    CHF Solutions Announces Launch of Aquapheresis Therapy Using Aquadex FlexFlow® System at the Baylor Scott & White Health System in Texas

    CHF Solutions (CHFS) today announced that Texas-based health system, Baylor Scott & White Health has initiated offering aquapheresis therapy using the company’s Aquadex FlexFlow® system at its Baylor Scott & White Medical Center in Temple, Texas. “Fluid overload continues to be an issue to be managed in the acute and chronic care settings, and CHF Solutions’ Aquadex FlexFlow System has continually proven to be a viable and easy-to-maintain solution for managing these patients and improving their quality of life while reducing the cost of care,” said John Erb, CEO of CHF Solutions.

  • GlobeNewswire

    CHF Solutions Announces Presentation of Clinical Data with Aquadex FlexFlow® Highlighting Efficacy and Simplicity of Use In Treating Critical Care Patients

    CHF Solutions (CHFS) today announced results from an investigator-initiated retrospective analysis of utilization of the Aquadex FlexFlow aquapheresis system at Lenox Hill Hospital in New York City. “We have found that aquapheresis with Aquadex FlexFlow can be safely utilized in situations other than diuretic resistant heart failure, such as critical care in patients experiencing cardiogenic shock, anasarca, ATN with fluid overload, ESRD with bridge ultrafiltration between hemodialysis treatment, and post-op volume overload,” said Dr. Maria V. DeVita, Nephrologist, Lenox Hill Hospital.

  • GlobeNewswire

    CHF Solutions Announces Launch of Ultrafiltration Therapy Using Aquadex FlexFlow® System at Memphis Methodist Le Bonheur Healthcare System

    CHF Solutions (CHFS) today announced that Memphis, Tennessee-based health system, Methodist Le Bonheur, has initiated offering aquapheresis therapy to patients suffering from fluid overload using the company’s Aquadex FlexFlow system. “As a company, we are dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation,” said John Erb, CEO of CHF Solutions.

  • GlobeNewswire

    CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    CHF Solutions, Inc. (CHFS), today announced that, on November 12, 2019, the independent directors approved eight equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to eight individuals entering into employment with the Company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with CHF Solutions, the eight individuals, who were not previously employees or directors of CHF Solutions, received options to purchase an aggregate of 77,500 shares of the Company’s common stock.

  • GlobeNewswire

    CHF Solutions, Inc. Announces Third Quarter Financial Results and Provides Company Update

    EDEN PRAIRIE, Minn., Nov. 05, 2019 -- CHF Solutions, Inc. (Nasdaq: CHFS), a medical device company focused on developing, manufacturing and commercializing a clinically proven.

  • GlobeNewswire

    CHF Solutions, Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market

    CHF Solutions, Inc. (CHF Solutions or the Company) (CHFS) today announced the pricing of a registered direct offering of 1,219,076 shares of its common stock (or common equivalents) at a price to the public of $1.12 per share, for gross proceeds of approximately $1.36 million prior to deduction of commissions and offering expenses payable by CHF Solutions. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 1,219,076 shares of the Company’s common stock.

  • GlobeNewswire

    CHF Solutions, Inc. Announces Sales Force Realignment To Increase Focus On Cardiac Surgery And Eventually Pediatrics

    CHF Solutions, Inc. (CHFS), a medical device company focused on developing, manufacturing and commercializing a clinically proven solution for diuretic-resistant patients suffering from fluid overload, announced a sales force realignment to increase focus on cardiac surgery and eventually pediatrics, following anticipated clearance from the FDA of its 510(k) application submitted in September 2019. “Over the past several months, we have been transitioning our commercial focus to the acute needs of fluid overloaded patients in cardiac surgery and other areas of critical care. As a result of these transitions, we are refocusing our sales team to better meet the needs of these markets,” said John Erb, chairman and CEO of CHF Solutions.

  • GlobeNewswire

    CHF Solutions, Inc. To Announce Third Quarter 2019 Financial Results and Corporate Update on November 5, 2019

    EDEN PRAIRIE, Minn., Oct. 29, 2019 -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its third quarter 2019 financial results will be released on Tuesday, November 5,.

  • GlobeNewswire

    Abington Hospital Begins a 344 Patient Retrospective Clinical Study to Analyze Experience with CHF Solutions’ Aquadex FlexFlow® System

    CHF Solutions (CHFS) today announced that investigators at Abington Hospital-Jefferson Health in Abington, Pennsylvania are conducting a retrospective analysis of their experience using the company’s Aquadex FlexFlow System in heart failure patients with fluid overload. The study, titled “Retrospective Review of a Single Center Experience with Aquapheresis in the Treatment of 344 Heart Failure Patients with Volume Overload,” is designed to identify patient characteristics, ultrafiltration rates, and renal function response to the utilization of aquapheresis therapy with the Aquadex FlexFlow system.

  • GlobeNewswire

    CHF Solutions, Inc. Announces Pricing of Registered Direct Offering

    CHF Solutions, Inc. (CHF Solutions or the Company) (CHFS) today announced the pricing of a registered direct offering of 575,830 shares of its common stock at a price to the public of $1.15 per share, for gross proceeds of approximately $660,000, prior to deduction of commissions and offering expenses payable by CHF Solutions.  In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 575,830 shares of the Company’s common stock.

  • GlobeNewswire

    CHF Solutions to Exhibit at The American College of Chest Physicians (CHEST) Annual Meeting 2019

    CHF Solutions, Inc. (CHFS) today announced that it will be exhibiting at the American College of Chest Physicians’ (CHEST) Annual Meeting 2019, on October 21-23, 2019. The conference will be held at the Ernest N. Morial Convention Center in New Orleans, La.  The company will be found at Exhibit Booth #2626. CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovative technology.

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • CHF Solutions System to be Used in JAHVH Study After Final Nod
    Zacks

    CHF Solutions System to be Used in JAHVH Study After Final Nod

    CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.

  • GlobeNewswire

    CHF Solutions Announces that James A. Haley Veterans’ Hospital Receives Final Approval To Initiate Heart Failure Outpatient Study utilizing Aquadex FlexFlow® System

    First Study of Aquadex FlexFlow System Sponsored by United States Veterans Administration for Aquapheresis Treatment in Patients Suffering from Fluid Overload. EDEN PRAIRIE, Minn., Oct. 10, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (CHFS), today announced that James A. Haley Veterans’ Hospital and Clinics (JAHVH), located in Tampa, Florida, has received Institutional Review Board approval to initiate an outpatient study using the Aquadex FlexFlow system (ultrafiltration therapy) to assist in the management of fluid overload in patients suffering from heart failure. In July 2018, CHF Solutions had announced that the Department of Veterans Affairs had awarded blanket purchase agreement for up to $6.5 million to the Company to supply the ultrafiltration therapy for a period of up to 5 years.

  • GlobeNewswire

    CHF Solutions, Inc. to Present at the MicroCap Rodeo Investor Conference on October 15, 2019

    EDEN PRAIRIE, Minn., Oct. 08, 2019 -- CHF Solutions, Inc. (Nasdaq: CHFS) today announced that John Erb, the company’s chairman and CEO, will be presenting and meeting with.

  • GlobeNewswire

    CHF Solutions To Exhibit at Upcoming Heart Failure Conferences

    EDEN PRAIRIE, Minn., Oct. 03, 2019 -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced that it will be exhibiting at two Heart Failure conferences during October: Mount.

  • GlobeNewswire

    CHF Solutions submits 510(k) application for Use of Aquadex FlexFlow® System with Pediatric Patients

    CHF Solutions, Inc. (CHFS) today announced that it has submitted an application to the FDA requesting for 510(k) clearance of the Aquadex FlexFlow system to include pediatric patients who weigh 20kg or more. Subject to FDA review, the company expects clearance for this pediatric population by the end of the year. “We are excited to have achieved this significant milestone in our corporate strategy to make the Aquadex FlexFlow technology available to pediatric patients,” said John L. Erb, chairman and CEO of CHF Solutions.

  • Market Exclusive

    Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests

    British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acted unlawfully in suspending Parliament until October 14th, and that he misled the Queen in advising that Parliament should be suspended. Johnson is now facing calls to resign, which […]The post Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests appeared first on Market Exclusive.

  • GlobeNewswire

    Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patients

    CHF Solutions, Inc. (CHFS) today announced the publication of a multi-center, retrospective study in the Clinical Journal of the American Society of Nephrology1 evaluating the use of hemofiltration and ultrafiltration therapy with the company’s Aquadex FlexFlow system in pediatric patients. The Aquadex FlexFlow system is not yet cleared by FDA for use in pediatric patients.

  • ACCESSWIRE

    The MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas

    Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...

  • GlobeNewswire

    CHF Solutions, Inc. to Present at the Ladenburg Thalmann’s 2019 Healthcare Conference on September 24, 2019

    EDEN PRAIRIE, Minn., Sept. 19, 2019 -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced that Claudia Napal Drayton, the company’s CFO, will be presenting and meeting with.

  • GlobeNewswire

    CHF Solutions, Inc. to Host a Call with Investigator Panel to Discuss Results of a Study Involving Use of Aquadex FlexFlow® in Pediatric Patients on September 25, 2019

    EDEN PRAIRIE, Minn., Sept. 17, 2019 -- CHF Solutions, Inc. (NASDAQ: CHFS) announced today that it will host a conference call and webcast at 1:00 PM ET on Wednesday, September.

  • GlobeNewswire

    CHF Solutions, Inc. to Exhibit at the 23rd Annual Scientific Meeting of the Heart Failure Society of America

    EDEN PRAIRIE, Minn., Sept. 10, 2019 -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced it would be exhibiting at the 23rd Annual Scientific Meeting of the Heart Failure.